Nuformix plc (LON:NFX)

Market Cap	2.87M -44.7%
Revenue (ttm)	n/a
Net Income	-622.50K
EPS	-0.00
Shares Out	2.61B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,356,831
Open	0.1100
Previous Close	0.1150
Day's Range	0.1000 - 0.1100
52-Week Range	0.1000 - 0.5600
Beta	1.55
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 30, 2026

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NX...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3
• Stock Exchange: London Stock Exchange
• Ticker Symbol: NFX

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 16, 2026

Data Sources Report a data error